Valneva SE update
Sign up for myFT Daily Digest and be the first to learn about Valneva SE news.
The United Kingdom has terminated its agreement with France-based biotechnology company Valneva for the supply of at least 100 million doses of Covid-19 vaccine, saying the company has violated its obligations under the agreement.
The company “strongly” denied this statement in a statement on Monday. The transaction is valued at 1.4 billion euros, manufacturing will take place in Scotland, and deliveries will begin in 2022.
Candidate vaccines use a complete inactivated virus to trigger an immune response against the coronavirus. This technology can extend the manufacturing process, but it can also provide greater coverage for all variants. Most other injections are aimed at the spike protein of the virus.
company It had previously warned that because of its supply chain, exporting vaccines between the EU and the UK would pose a “significant risk” to its plan. In Sweden, injections are put in vials.
It is not clear what prompted the British government to issue the termination notice.
Valneva said that the vaccine is in an advanced stage of testing and is expected to receive results and UK approval in the fourth quarter and the end of next year, respectively.
The drugmaker said in a statement that it “worked tirelessly and did its best” in its cooperation with the UK, adding that it will increase its efforts to ensure that other potential customers can use its vaccines to fight the epidemic. .